VSM Nederland

Belkins
VSM has long been a household name in the home care market. Our brands include Spiroflor®, Calendulan®, Cardiflor® and specifically known and popular with young parents, our children's series VSM Child.

Related News

NEW JERSEY PHARMACEUTICAL COMPANY DONATES 400,000 TABLETS TO LOUISIANA FOR CLINICAL TRIALS IN COVID-19 TREATMENT

WBRZ- | March 30, 2020

news image

Louisiana Attorney General Jeff Landry, working with the assistance of State Senate Health and Welfare Chairman Fred Mills issued a statement Monday, announcing that Amneal Pharmaceuticals is donating 400,000 hydroxychloroquine sulfate tablets to the State of Louisiana to assist with the COVID-19 pandemic. "On behalf of Louisiana, I want to thank Amneal for this generous donation," said General Landry. "Amneal's donation is one step toward trying to find treatments and cures f...

Read More

BUSINESS INSIGHTS

DERMALIQ THERAPEUTICS SIGNS USD 15 MILLION SERIES A ROUND TO ADVANCE THREE TRANSFORMATIVE DRUG THERAPIES INTO CLINICAL TRIALS

Dermaliq Therapeutics | January 18, 2022

news image

Novaliq GmbH, 3E Bioventures Capital and Beijing Whale Technology Corporation Ltd. today announced the establishment of Dermaliq Therapeutics, Inc (Dermaliq), a newly formed Delaware-based pharmaceutical development company, and the signing of a USD 15 million Series A financing round. 3E Bioventures Capital, a leading international life science investor, led the round and was joined by Beijing Whale Technology Corporation Ltd. Dermaliq's existing shareholder Novaliq has transferred, and lic...

Read More

RESEARCH

ORSINI SPECIALTY PHARMACY EXPANDS COLLABORATES WITH ALNYLAM® PHARMACEUTICALS AS A LIMITED DISTRIBUTION PARTNER FOR OXLUMO™

Orsini | December 04, 2020

news image

Orsini Specialty Pharmacy, an innovator in uncommon illnesses and quality treatments, reported today that it has been chosen by Alnylam® Pharmaceuticals as a restricted appropriation accomplice for OXLUMO™ (lumasiran). OXLUMO is the solitary treatment affirmed for essential hyperoxaluria type 1 (PH1) to bring down urinary oxalate levels in pediatric and grown-up patients. PH1 is a super uncommon hereditary sickness described by the overproduction of oxalate, a side-effec...

Read More

BUSINESS INSIGHTS

OPTEL ACQUIRES PHARMA TRACK-AND-TRACE UNIT OF KÖRBER

OPTEL Group | January 12, 2022

news image

OPTEL GROUP, already a world leader in supply chain traceability, is expanding its expertise and global reach with the recent acquisition of the track-and-trace unit of the Körber Business Area Pharma, formerly known as Traxeed, based in Germany. Körber is a leading international technology group. The acquisition, announced today, will allow OPTEL to leverage the unit's expertise in pharmaceutical and agrochemical track-and-trace technologies, provide the company wit...

Read More
news image

NEW JERSEY PHARMACEUTICAL COMPANY DONATES 400,000 TABLETS TO LOUISIANA FOR CLINICAL TRIALS IN COVID-19 TREATMENT

WBRZ- | March 30, 2020

Louisiana Attorney General Jeff Landry, working with the assistance of State Senate Health and Welfare Chairman Fred Mills issued a statement Monday, announcing that Amneal Pharmaceuticals is donating 400,000 hydroxychloroquine sulfate tablets to the State of Louisiana to assist with the COVID-19 pandemic. "On behalf of Louisiana, I want to thank Amneal for this generous donation," said General Landry. "Amneal's donation is one step toward trying to find treatments and cures f...

Read More
news image

BUSINESS INSIGHTS

DERMALIQ THERAPEUTICS SIGNS USD 15 MILLION SERIES A ROUND TO ADVANCE THREE TRANSFORMATIVE DRUG THERAPIES INTO CLINICAL TRIALS

Dermaliq Therapeutics | January 18, 2022

Novaliq GmbH, 3E Bioventures Capital and Beijing Whale Technology Corporation Ltd. today announced the establishment of Dermaliq Therapeutics, Inc (Dermaliq), a newly formed Delaware-based pharmaceutical development company, and the signing of a USD 15 million Series A financing round. 3E Bioventures Capital, a leading international life science investor, led the round and was joined by Beijing Whale Technology Corporation Ltd. Dermaliq's existing shareholder Novaliq has transferred, and lic...

Read More
news image

RESEARCH

ORSINI SPECIALTY PHARMACY EXPANDS COLLABORATES WITH ALNYLAM® PHARMACEUTICALS AS A LIMITED DISTRIBUTION PARTNER FOR OXLUMO™

Orsini | December 04, 2020

Orsini Specialty Pharmacy, an innovator in uncommon illnesses and quality treatments, reported today that it has been chosen by Alnylam® Pharmaceuticals as a restricted appropriation accomplice for OXLUMO™ (lumasiran). OXLUMO is the solitary treatment affirmed for essential hyperoxaluria type 1 (PH1) to bring down urinary oxalate levels in pediatric and grown-up patients. PH1 is a super uncommon hereditary sickness described by the overproduction of oxalate, a side-effec...

Read More
news image

BUSINESS INSIGHTS

OPTEL ACQUIRES PHARMA TRACK-AND-TRACE UNIT OF KÖRBER

OPTEL Group | January 12, 2022

OPTEL GROUP, already a world leader in supply chain traceability, is expanding its expertise and global reach with the recent acquisition of the track-and-trace unit of the Körber Business Area Pharma, formerly known as Traxeed, based in Germany. Körber is a leading international technology group. The acquisition, announced today, will allow OPTEL to leverage the unit's expertise in pharmaceutical and agrochemical track-and-trace technologies, provide the company wit...

Read More

Resources

resource image

BUSINESS INSIGHTS

2021 global life sciences outlook

infographic

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us